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Abstract
Background: While premature suture fusion, or craniosynostosis, is a relatively common condition, the cause is often
unknown. Estrogens are associated with growth plate fusion of endochondral bones. In the following study, we explore the
previously unknown significance of estrogen/estrogen receptor signaling in cranial suture biology.
Methodology/Principal Findings: Firstly, estrogen receptor (ER) expression was examined in physiologically fusing
(posterofrontal) and patent (sagittal) mouse cranial sutures by quantitative RT-PCR. Next, the cranial suture phenotype of ER
alpha and ER beta knockout (aERKO, bERKO) mice was studied. Subsequently, mouse suture-derived mesenchymal cells
(SMCs) were isolated; the effects of 17-b estradiol or the estrogen antagonist Fulvestrant on gene expression, osteogenic
and chondrogenic differentiation were examined in vitro. Finally, in vivo experiments were performed in which Fulvestrant
was administered subcutaneously to the mouse calvaria. Results showed that increased ERa but not ERb transcript
abundance temporally coincided with posterofrontal suture fusion. The aERKO but not bERKO mouse exhibited delayed
posterofrontal suture fusion. In vitro, addition of 17-b estradiol enhanced both osteogenic and chondrogenic differentiation
in suture-derived mesenchymal cells, effects reversible by Fulvestrant. Finally, in vivo application of Fulvestrant significantly
diminished calvarial osteogenesis, inhibiting suture fusion.
Conclusions/Significance: Estrogen signaling through ERa but not ERb is associated with and necessary for normal mouse
posterofrontal suture fusion. In vitro studies suggest that estrogens may play a role in osteoblast and/or chondrocyte
differentiation within the cranial suture complex.
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Introduction
Craniosynostosis, or the premature osseous obliteration of
cranial sutures, is a relatively common craniofacial defect, with
an incidence of 1 in 2500 live births [1]. Its clinical sequelae can be
significant, and include both morphologic and functional abnor-
malities [2]. Our laboratory has investigated the mechanisms of
cranial suture fusion using a mouse model, with the hopes that a
more thorough understanding of physiologic suture fusion may
lead toward novel therapeutics for pathologic synostosis [3].
In the mouse, the posterofrontal (PF) suture fuses in the first
weeks of life, whereas all other sutures remain patent, including the
contiguous sagittal (SAG) suture [3,4]. The PF suture normally
fuses through a cartilage intermediate, or via endochondral
ossification [4]. In these respects, the mouse PF suture is analogous
to the human metopic suture, which fuses during infancy [5,6].
The molecular comparison of PF and SAG cranial sutures, as
exemplars of normal suture fusion and suture patency, respective-
ly, has led to the identification of differences in locally acting
cytokines between fusing and patent sutures, including FGF-2,
IGFs, TGF-bs, and BMP agonists and antagonists [7–11]. While
much study has focused on the role of autocrine and paracrine
signaling in cranial suture biology, the role of endocrine signaling
in suture formation and fusion has been relatively unexplored
[12,13].
Estrogens have been shown to be important in the development
and maintenance of the appendicular skeleton [14]. Estrogens
have two known nuclear receptors, estrogen receptor (ER) a and
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b. Both receptors are present in the epiphyseal growth plate,
specifically in hypertrophic chondrocytes, as well as adjacent bony
tissues [15–18]. The mechanisms by which estrogens act locally on
the growth plate are poorly understood. It has been proposed that
estrogen initiates the pubertal growth spurt by stimulating
chondrogenesis and inhibiting chondrocyte apoptosis [19].
Additionally, estrogens are postulated to contribute to growth
plate fusion via endochondral ossification, possibly by estrogen-
induced vasculogenesis and/or osteoblast invasion [20,21].
Despite the imprecise role of estrogen in growth plate fusion,
perturbations of estrogen signaling indicate its importance. Both
the ERa and ERb knockout mice (aERKO and bERKO) possess
a skeletal phenotype. The aERKO mouse has been observed to
have a more severe phenotype, including reduced bone mineral
density and bone mineral content, as well as decreased
longitudinal and radial bone growth [14,22–26]. Absence of the
tibial growth plate cartilages has also been previously observed in
female aERKO mice [26]. In contrast, the bERKO mouse has
been observed to have a relatively minor phenotype, reported
either to have normal or increased appendicular and axial-skeletal
growth [24,27,28]. Human perturbations in estrogen signaling
have been observed to differ from those in mice: patients with
mutations in ERa or aromatase P-450 present with delayed or
incomplete ossification of the growth plates [29–31]. While
estrogen’s involvement in longitudinal bone growth has been
studied in depth, its role in cranial suture biology has not been
defined. We hypothesized that estrogen may influence the PF
suture in a similar manner to its role in ossification of the
epiphyseal plate.
In this study, we first examined temporal and spatial patterns of
ER expression in the posterofrontal (PF, fusing) and sagittal (SAG,
patent) sutures. Next, we inquired as to the necessity of estrogen
signaling in cranial suture fusion by examining the suture
phenotype of the aERKO and bERKO mutant mice. We
employed in vitro culture of calvarial-derived cells to explore in
detail the cellular impacts of estrogen signaling, utilizing both 17-b
estradiol (E2) and the pan-ER antagonist Fulvestrant (ICI
182,780). Finally, in vivo biochemical perturbations were per-
formed by applying Fulvestrant to developing wild-type cranial
sutures.
Results
Gross and histological morphology of Posterofrontal and
Sagittal cranial sutures
Our laboratory has previously identified a timeline of normal PF
suture fusion: the initiation of fusion occurs at or around postnatal
day 7 (p7), the most prominent cartilaginous intermediate is
observed at p10, and osseous closure is for the most part complete
by p19 [4]. We sought to confirm this by whole mount bone and
cartilage preparations of mouse calvariae, (Fig. S1). In the murine
skull, the PF suture lies anterior to the contiguous SAG suture,
which lies posterior (Fig. S1A). At p4, the calvarial bones are
widely separated by suture mesenchyme (Fig. S1A). Intermittent
bony bridging of the PF suture is apparent at or around p10,
primarily in the anterior aspect of the suture (Fig. S1C). By
p19, the majority of the PF suture has undergone osseous fusion,
with intermittent gaps of patency (Fig. S1F). In contrast, the SAG
suture remains patent in its entirety, throughout adult life
(Fig. S1A–F).
Histological analysis of PF and SAG sutures reveals more
developmental detail, (Fig. S2). Pentachrome staining was
performed at identical time points (p4–p19), in which bone
appears yellow, while cartilage appears blue/green. As the
histologic appearance of PF and SAG sutures exhibits variation
along the anterior-posterior axis, representative sections from the
anterior aspect of each suture were chosen. At p4, the osteogenic
fronts of both PF and SAG sutures are widely separated by an
undifferentiated cellular mesenchyme, (Fig. S2A,B,G,H). From p7
to p10, a blue/green cartilaginous intermediate appears on the
endocranial aspect of the PF suture (Fig. S2C-F). At p16 onwards,
the endocranial mesenchyme of the PF suture is replaced by bony
tissue seen as yellow (i.e. fused) (Fig. S2O-R). In contrast, the
osteogenic fronts of the SAG suture remain separated by a cellular
mesenchyme at all time points (i.e. patent), and either appear in an
end-to-end or slightly overlapping fashion (Fig. S2G–L,S–X).
Estrogen receptor gene expression in PF and SAG cranial
sutures
Having confirmed a timeline for PF suture fusion, estrogen
receptor expression was examined by qRT-PCR. Expression of
both nuclear receptors, ERa and ERb, was assayed in PF (fusing)
as well as SAG (patent) cranial sutures, (Fig. 1A,B). Results showed
that ERa transcript abundance in the PF suture increased over the
time course of suture fusion, (red bars, Fig. 1A). Before the process
of suture fusion (p4), ERa expression was approximately equal
between PF and SAG sutures (far left, Fig. 1A, N= 10). From p4 to
p10, a greater than 12-fold increase in ERa was observed,
(corresponding to a time period of growth and chondrogenesis
within the PF suture, (red bars Fig. 1A, *P,0.01). Thereafter, ERa
expression gradually decreased, but remained significantly elevat-
ed, (a time period corresponding to gradual suture ossification, red
bars Fig. 1A, *P,0.01). ERa expression was present to a lesser
degree in the non-fusing SAG suture, (blue bars Fig. 1A,
#P,0.01). While ERa expression peaked during fusion of the
PF suture, ERb expression remained relatively constant overtime
in both PF and SAG suture complexes, (Fig. 1B). Expression of the
chondrogenic transcription factor Sex determining region Y-box 9 (Sox9)
was also evaluated, (Fig. 1C). The peak in transcript abundance for
both Sox9 and ERa temporally coincided at p10, a time point at
which histological evidence of chondrocytes is most apparent in
the PF suture, (Fig. 1C, see also Supplemental Fig. 2,E,F, N,
*P,0.01). Data of Sox9 expression are in agreement with previous
observations by our laboratory [4]. In summary, these data
temporally associated ERa gene expression with mouse PF suture
fusion.
Estrogen receptor protein expression in PF and SAG
cranial sutures
Having observed a dynamic change in ERa gene expression, we
next examined the spatial distribution of ERa protein expression
in the fusing PF and patent SAG sutures, by immunohistochem-
istry (Fig. 1D–I). In the PF suture, strong nuclear staining for ERa
was observed most prominently in hypertrophic chondrocytes in
the suture mesenchyme, (Fig. 1E). Less prominent staining was
observed within the pericranium, as well as osteoblasts lining and
osteocytes within the frontal bones. For comparison in the SAG
suture, immunostaining for ERa protein was limited to those cells
encircling the osteogenic fronts of the growing parietal bones,
(Fig. 1H). Pentachrome staining of adjacent sections are provided
for orientation (Fig. 1D,G); negative controls without exposure to
primary antibody are presented as well (Fig. 1F,I). Notably, no
significant differences in staining for ERs were observed between
sutures taken from male or female mice, a finding similar to
previously published observation in the murine tiba [15,16]. In
summary, ERa protein is expressed in both PF and SAG sutures.
Its spatial distribution suggests that cells undergoing both
Estrogen in Cranial Sutures
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osteogenesis and chondrogenesis within the developing cranial
suture expressed ER protein. In addition, cells within the suture
mesenchyme of the non-fusing SAG suture stained to a relatively
lesser degree for ER protein than chondrocytes within the fusing
PF suture.
ERa but not ERb null mice exhibit delayed PF suture
fusion
While ER expression was associated with PF suture fusion, the
necessity of ER signaling in suture fusion had not yet been
assessed. For this purpose, genetic knockout mice were analyzed
lacking either functional ERa or ERb. Analysis of the PF suture
was performed at postnatal time points spanning the process of
suture fusion: p10, p16 and p30. As the PF suture exhibits
variation in development along its anterior-posterior axis, the
entirety of each suture was sectioned and every 5th section was
stained for histological analysis (Fig. 2).
In the p10 PF wild-type (WT) suture a large cartilaginous
intermediate was normally observed within the mid-sutural space
(Fig. 2A). Cartilage was observed in the majority of sections, and
found in all WT sutures (5/5 specimens). In the corresponding
aERKO sutures, the PF suture was observed to be patent throughout
and without a cartilage intermediate, (Fig. 2B) (3/3 specimens).
Cellular proliferation was assayed in WT and aERKO by PCNA
Figure 1. Estrogen receptor a and b expression in PF and SAG sutures. (A) ERa gene expression in PF and SAG sutures by qRT-PCR,
normalized to GAPDH. Expression increased over 12-fold from postnatal ages 4 to 10 in the fusing PF suture, see red bars. Highest expression was
noted at p10, temporally corresponding with PF suture fusion. (B) ERb gene expression in PF and SAG sutures, normalized to GAPDH. Expression
remained relatively constant over the time course examined in both PF and SAG sutures. (C) Sox9 gene expression in PF and SAG sutures, normalized
to GAPDH. (D) Pentachrome staining of the p7 PF suture in which cartilage appears blue/green, while bone appears yellow. (E) ERa
immunohistochemistry of p7 PF suture. Nuclear ERa protein strongly localizes to hypertrophic chondrocytes within the PF suture; dashed lines
indicate the fusing inner bone table of the suture. (F) Negative control for ERa immunohistochemistry. (G) Pentachrome staining of the p7 SAG
suture. (H) ERa immunohistochemistry of p7 SAG suture. Dashed lines indicate the adjacent osteogenic fronts of the patent suture. (I) Negative
control for ERa immunohistochemistry. Gene expression values are normalized to expression within the p4 SAG suture complex, N= 10, *, **, and
#P#0.01 in which * signifies differences between the PF suture at various timepoints, ** between SAG suture at various timepoints, and # between
PF and SAG sutures at the same timepoint. Histological sections are from the anterior aspect of PF and SAG sutures, presented at 406magnification.
doi:10.1371/journal.pone.0007120.g001
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immunostaining, which showed a relative paucity of PCNA+ cells in
the knockout PF suture (Fig. 2C,D). Further difference in gene
expression were evaluated by in situ hybridization (Fig. 2E–H). In the
WT frontal bone, those cells lining and within the calvarial bone
stained strongly for Runx2, while relatively less staining was observed
in the aERKO frontal bone (Fig. 2E,F). Moreover, in the WT PF
suture, hypertrophic chondrocytes were noted to stain strongly for
Sonic Hedgehog (Shh), by in situ hybridization (Fig. 2G). In contrast, little
Shh expression was observed in the aERKO PF suture (Fig. 2H). By
postnatal day 16, the majority of the WT PF suture exhibited osseous
fusion on the endocranial surface, (Fig. 2I). In contrast, only sporadic
fusion was noted in the aERKO PF suture, (Fig. 2J). Percentage
fusion was calculated by examination of every 5th slide (N=5 WT,
N=3 aERKO sutures). Results showed that the majority of the WT
PF suture exhibited fusion along its anterior-posterior axis by p16
(66%), whereas on average only 12% of the aERKO PF suture was
Figure 2. PF suture phenotype in aERKO mouse. (A) Wild-type (WT) p10 PF suture. Hypertrophic chondrocytes, seen here as blue/green, are
observed to bridge the gap between osteogenic fronts of the suture. (B) aERKO p10 PF suture. A complete absence of cartilage is observed, despite
proximity of the osteogenic fronts. (C) PCNA immunohistochemistry in the WT p10 PF suture. (D) PCNA staining in the aERKO p10 PF suture showed
relatively less staining. (E) In situ hybridization for Runx2 in the WT p10 frontal bone. Strong staining was noted in the cells lining and within the bone.
(F) In comparison, less staining was observed in the aERKO frontal bone (G) In situ hybridization for Shh in the WT p10 PF suture. Strong staining was
noted in the hypertrophic chondrocytes within the suture mesenchyme. (H) In comparison, little staining for Shh was noted in the aERKO p10 PF
suture. (I) WT p16 PF suture. Note normal osseous fusion on the endocranial aspect. (J) aERKO p16 PF suture. Suture patency is apparent on both
endo- and ectocranial aspects. (K) Mean percentage suture fusion in WT, aERKO and bERKO PF p16 sutures. Every 5th coronal section of the suture
was stained; two blinded, independent observers judged fusion or patency along the length of the suture. (L) Relative gene expression in WT as
compared to aERKO whole skulls at 7d of life, as determined by qRT-PCR. Averages and standard deviations were calculated, significance calculated
relative to wild-type percentage fusion, *P,0.01. For histological specimens, sections presented are taken from the anterior aspect of the PF suture,
presented at 206–406magnification.
doi:10.1371/journal.pone.0007120.g002
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fused along its length (Fig. 2K, *P,0.01). This difference in PF fusion
was observed in 30d old mice as well: while osseous fusion was
apparent throughout the length of the PF suture in the WT and with
only small gaps of patency (N=4), only the anterior portion of
aERKO PF suture showed evidence of fusion and osteogenic fronts
remained separated (data not shown). Analysis of the bERKO PF
suture revealed no difference to WT sutures (Fig. 2K for
quantization). Moreover, no differences in SAG suture morphology
were observed between wild-type, aERKO, or bERKO mice (data
not shown). Collectively, these data demonstrated that the aERKO
but not the bERKOmouse exhibited delayed fusion of the PF suture,
without evidence of a chondrocytic intermediate and with diminished
Hedgehog expression.
To verify differences between wild-type and aERKO mice
observed by histology, gene expression in whole skulls was
examined in 7d old littermates. Briefly, numerous genes involved
in osteochondrogenic differentiation were observed to be de-
creased in expression in the aERKO calvaria, including Runx2,
Sox9 and alkaline phosphatase (ALP) (Fig. 2L). Moreover, growth and
differentiation factors such as BMP-2, -4, and -7, as well as Sonic
Hedgehog were down-regulated as well (Fig. 2L, right).
While ERa mutations resulted in a mouse suture phenotype, the
underlying mechanisms that translated a biochemical deficiency
into a craniofacial dysmorphism remained unclear. To elucidate
possible mechanisms, we next turned to in vitro culture of suture-
derived mesenchymal cells (SMCs), of which the procedure has
been previously described [7,8,32]. In vitro, estrogen signaling was
either artificially increased with the addition of 17-b estradiol (E2),
or decreased with addition of the synthetic, pan-ER antagonist
Fulvestrant (ICI 182,780).
17-b Estradiol increases cellular proliferation of PF suture-
derived mesenchymal cells, reversible by Fulvestrant
Posterofrontal suture-derived mesenchymal cells (SMCs) were
isolated from p4 animals, a time period where the PF suture is
widely patent, separated by an undifferentiated cellular mesen-
chyme (see also Supplemental Fig. 2A,B for histology). To assess
the effects of estrogen signaling in SMCs, both E2 and the ER
antagonist Fulvestrant were added to medium, alone or in
combination; in vitro studies included proliferation, osteogenic
and chondrogenic differentiation assays. Effects on cellular
proliferation were first examined by BrdU incorporation assays
(Fig. 3). At both 3 and 6d growth, E2 was observed to increase
BrdU incorporation, (Fig. 3A, 0.1–10 nM, N=6, *P,0.01). No
effect was observed with blockade of estrogen signaling via
Fulvestrant addition to medium alone (left Fig. 3B, 0.1–10 uM).
By combining Fulvestrant with E2, the mitogenic effect of E2 was
reversed, (right Fig. 3B, 10 nM estradiol, 0.1–10 uM Fulvestrant,
*P,0.01).
17-b Estradiol increases osteogenic differentiation of PF
suture-derived mesenchymal cells
Estrogens have been shown to promote osteogenesis in disparate
cell types, both in vitro and in vivo [33–39]. To assess the osteogenic
effects of E2 on SMCs, firstly, ERa and ERb gene expression were
evaluated throughout osteogenic differentiation (0, 1 and 2 wks in
osteogenic differentiation medium). As has been reported in other
cell types, expression of both ERa and ERb were observed to
increase overtime in osteogenic medium, (Fig. 4A, N= 3, *P,0.01)
[37,40]. After 7d differentiation, staining and quantification of
alkaline phosphatase (ALP) activity was performed as an early
marker of osteogenic differentiation (Fig. 4B,C). Results showed
that E2 increased both the intensity of ALP staining, and absolute
value of enzymatic activity when normalized to total protein
content (Fig. 4B,C, N= 3, *P,0.01). Terminal osteogenic
differentiation was assessed at 14d differentiation, by Alizarin
red staining of bone nodules and colorimetric quantification
(Fig. 4B,D, N= 3, *P,0.01). Congruent with ALP activity,
Alizarin Red staining demonstrated a dose-dependent increase
with E2 addition (Fig. 4B,D). Gene expression of osteogenic
Figure 3. Cellular proliferation of PF SMCs with 17-b Estradiol and Fulvestrant. After 3 and 6d growth with or without 17-b estradiol (0.1–
100 nM), BrdU incorporation assays were performed to evaluate cellular proliferation. (A) BrdU incorporation with or without 17-b estradiol.
Treatment with 17-b estradiol (E2) resulted in increased proliferation (0.1–10 nM). (B) BrdU incorporation after 6d growth with Fulvestrant alone or in
combination with 17-b estradiol. Fulvestrant alone showed no effect on BrdU uptake (left), while in combination with E2 was observed to reverse the
mitogenic effect of E2 (right). Values are normalized and significance levels calculated relative to control groups in grey, N = 6, *P,0.01.
doi:10.1371/journal.pone.0007120.g003
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Figure 4. Osteogenic differentiation of PF SMCs with 17-b Estradiol. (A) ERa and ERb expression throughout osteogenic differentiation (0, 1
and 2 wks). (B, left) Enzymatic alkaline phosphatase activity normalized to total protein content after 7d differentiation with or without E2. (B, right)
Photometric quantification of Alizarin red staining after 14d differentiation with or without E2. (C) Alkaline phosphatase staining with or without E2
after 7d differentiation. (D) Alizarin red staining with or without E2 after 14d differentiation. (E, left) Expression of early markers of osteogenic
differentiation (Runx2, ALP and Col1a) at 4d differentiation with or without E2. (E, right) Osteocalcin expression after 14d differentiation with or
without E2. (F) Bmp2, Bmp4 and Bmp7 expression at 4d differentiation with or without E2. (G) Shh, Ihh, Gli1 and Ptc1 expression at 4d differentiation
with or without E2. Values are normalized and significance levels calculated relative to control groups in grey or 0 wk expression levels in blue,
photos are representative of random microscopical fields at 206magnification, N= 3, *P,0.01.
doi:10.1371/journal.pone.0007120.g004
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specific markers was assessed to verify E2 mediated enhancement
of in vitro osteogenesis (Fig. 4E). Consistent results were obtained
both with early markers (Runx2, ALP, Col1a1) and terminal
markers of differentiation (Osteocalcin): each showed a significant
increase in expression with E2 as compared to osteogenic medium
alone (Fig. 4E, N= 3, *P,0.01). Thus, E2 addition to osteogenic
medium enhanced SMC osteogenic differentiation.
Bone morphogenetic proteins (BMP)-2, -4 and -7 are members of
the BMP family important in osteogenic differentiation [41].
Molecular studies have indicated that E2 may promote osteogenic
differentiation in some cell types by promoting transcription of pro-
osteogenic bone morphogenetic proteins (BMPs); we sought to
investigate whether the same is true in SMCs [38,42–45].
Interestingly, Bmp2, -4, and -7 expression was observed to increase
with E2 addition to medium; a 2–4 fold up-regulation in each
cytokine was observed, (Fig. 4F, N=3, *P,0.01). Hedgehog
signaling via either Sonic Hedgehog (Shh) or Indian Hedgehog
(Ihh) has been observed to be of importance in both osteogenic and
chondrogenic differentiation, in vitro and in vivo [46–50]. We next
evaluated gene expression of Hedgehog ligands (Shh, Ihh) and
downstream signaling elements (Ptc1, Gli1) after E2 treatment, by
qRT-PCR. Interestingly, and as has been described in other cell types
[51], E2 increased transcript abundance for all Hedgehog signaling
elements examined, (Fig. 4G, N=3, *P,0.01). This suggested that
the pro-osteogenic effect of E2 in SMCs may be, in part, due to
increased transcription of BMP and Hh family members.
Fulvestrant decreases osteogenic differentiation of PF
suture-derived mesenchymal cells
Having shown that E2 positively influences SMC osteogenic
differentiation, we next inquired as to whether the converse was true:
whether blockade of endogenous estrogen signaling negatively
influenced in vitro osteogenesis. Fulvestrant, a synthetic pan-ER
antagonist, was added to osteogenic culture conditions (Fig. 5).
Fulvestrant has been observed to decrease osteogenic differentiation
of various bone forming cells in vitro [52–54]. Staining for ALP and
Alizarin red was performed as previously shown (Fig. 5A,B). While
SMCs in osteogenic medium alone showed relatively abundant
staining, Fulvestrant when added at all concentrations diminished the
intensity of staining for both ALP and Alizarin red staining (N=3, 1–
10 uM). Quantification of enzymatic ALP activity was next
performed with Fulvestrant, with or without E2 (Fig. 5C, N=3, *
and **P,0.01). Similar to results from biochemical staining, ALP
enzymatic activity was significantly reduced with Fulvestrant.
Moreover, E2 mediated up-regulation of ALP activity was reversed
by addition of Fulvestrant in combination (yellow bars Fig. 5C, N=3,
**P,0.01). Specific gene expression was examined by qRT-PCR,
demonstrating a significant decrease in gene markers of early as well
as terminal osteogenic differentiation (Runx2, Col1a, Osteopontin,
Osteocalcin, Fig. 5D, N=3, *P,0.01). We observed previously that
culture with E2 significantly increased a number of pro-osteogenic
cytokines, including BMP and Hh ligands (see Fig. 4). Interestingly,
we found the converse to be true as well: culture with Fulvestrant
resulted in a decrease in transcript abundance for Bmp2, Bmp4, Shh,
Ihh as well as downstream Hh signaling components (Gli1, Ptc1), by
qRT-PCR (Fig. 5E,F, N=3, *P,0.01). Thus, these data suggested
that inhibition of endogenous ER signaling impedes in vitro SMC
osteogenesis, accompanied by a decrease in BMP and Hh signaling.
17-b Estradiol increases chondrogenic differentiation of
PF suture-derived mesenchymal cells
Estrogen receptors are normally expressed in chondrocyte
growth plates and have been shown to positively regulate
chondrocyte maturation in various models [55–59]. Our previous
observations had suggested that in the PF suture as well, estrogen
signaling may play a role in chondrogenesis. For example, using
immunohistochemistry we previously noted that ER protein
expression was strongly present in chondrocytes within the PF
suture, (see also Fig. 1E). In addition, the aERKO mouse
demonstrated a complete lack of cartilage within the PF suture (see
also Fig. 2B,D). Therefore, we next inquired as to the effects of
estrogen signaling in the in vitro chondrogenic differentiation of
SMCs (Fig. 6).
Firstly, ERa and ERb expression were evaluated over 9d
chondrogenic differentiation by qRT-PCR. Results showed that
gene expression of both estrogen receptors increased after 6d in
chondrogenic medium, (Fig. 6A,B, N= 3, *P,0.01). We next
added E2 to chondrogenic medium and examined gene markers of
chondrogenic differentiation (10 nM). Expression of the transcrip-
tion factor Sox9, as well as extracellular matrix component Col II
were assessed, see (Fig. 6C,D, N=3, *P,0.01). PF SMCs showed
significantly increased expression of both Sox9 and Col II overtime
under chondrogenic condition (grey bars Fig. 6C,D, N=3,
*P,0.01). Addition, however, of E2 significantly increased both
Sox9 and Col II expression to a greater degree (yellow bars
Fig. 6C,D, N=3, #P,0.01). Thus, addition of E2 enhanced
markers not only of osteo- but also chondrogenic differentiation of
SMCs in vitro.
TGF-b1 induces chondrogenic differentiation of multiple cell
types in vitro and in vivo [8,60,61]. We examined Tgf-b1 gene
expression upon E2 addition to chondrogenic medium (Fig. 6E).
Without E2, Tgf-b1 gene expression was observed to decreased
overtime in chondrogenic culture (Fig. 6E, N= 3, *P,0.01). In
contrast, E2 addition led to a significant up-regulation of Tgf-b1
expression (Fig. 6E, **P,0.01). Thus, the pro-chondrogenic effect
of E2 in PF SMCs may in part be due to maintained TGF-b
signaling.
Fulvestrant inhibits calvarial osteogenesis in vivo
Genetic knockout models suggested that estrogen signaling
through ERa was necessary for normal PF suture fusion. We next
inquired whether iatrogenic, biochemical perturbation of ER
signaling could impede normal suture fusion in vivo. The
biochemical antagonist Fulvestrant was applied subcutaneously,
daily, to the midline of the mouse skull starting at p1 and applied
for the following 10 days (10 ul of a 100 uM solution). Various in
vivo applications of Fulvestrant have resulted in decreased bone
volume accompanied by increased bone turnover [62–64].
Animals injected with vehicle control appeared grossly and
histologically identical to non-manipulated animals and exhibited
normal suture morphology (Fig. 7A,C,E). In marked contrast,
those animals treated with Fulvestrant showed severely diminished
calvarial osteogenesis, accompanied by widely patent sutures
(N= 10, Fig. 7B,D,F). Cellular proliferation and cell death were
examined in control and Fulvestrant treated calvariae by BrdU
and TUNEL staining, respectively (Fig. 7G–J). A slight decrease in
cellular proliferation was observed in treated as compared to
control specimens. Positive TUNEL staining was sparsely
observed in both control and treated specimens; most staining
was observed among control specimens in those chondrocytes
undergoing apoptosis within the fusing PF suture. Quantification
of BrdU and TUNEL staining was performed using Adobe
Photoshop, normalized to total cell number, (Fig. 7Q). This
suggested that the phenotype observed with Fulvestrant treatment
was not likely due to a direct change in either cellular proliferation
or cell viability. We inquired as to whether Fulvestrant injection
resulted in widespread osteoclastogenesis and concomitant bone
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Figure 5. Osteogenic differentiation of PF SMCs with Fulvestrant. (A) Alkaline phosphatase staining with or without Fulvestrant after 7d
differentiation. (B) Alizarin red staining with or without Fulvestrant after 14d differentiation. (C) Enzymatic alkaline phosphatase activity normalized to
total protein content after 7d differentiation with or without Fulvestrant. (D, left) Runx2 and Col1a expression after 4d differentiation with or without
Fulvestrant. (D, right) Osteopontin and Osteocalcin expression after 14d differentiation with or without Fulvestrant. (E) Bmp2, Bmp4, and Bmp7
expression after 4d with or without Fulvestrant. (F) Shh, Ihh, Gli1, and Ptc1 after 4d differentiation with or without Fulvestrant. Values are normalized
and significance levels calculated relative to control groups in grey, photos are representative of random microscopical fields at 206magnification,
N = 3, *P,0.01.
doi:10.1371/journal.pone.0007120.g005
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turnover; this was assessed in treated and control calvariae by
TRAP staining. Again, no differences were observed, suggesting
that increased bone turnover could not explain the phenotype of
Fulvestrant treated calvaria (Fig. 7K,L,Q). Finally, gene expression
levels of Runx2 and Sonic hedgehog (Shh) were evaluated by in situ
hybridization (Fig. 7M–P). As previously observed in the aERKO
skull, Fulvestrant treatment resulted in diminished expression for
Runx2 and Shh. Although Runx2 expression was not appreciably
diminished, a slight difference in expression pattern was observed.
In summation, in this study we sought to correlate estrogen
signaling with mouse cranial suture fusion, a process of
endochondral ossification [4]. We found that ERa gene transcript
abundance temporally coincides with PF suture fusion. Moreover,
immunohistochemistry detected ER protein primarily within
osteocytes and chondrocytes in cranial suture mesenchyme. Via
analysis of ER knockout mice, functional ERa but not ERb was
found to be necessary for normal suture fusion. In vitro cell culture
of suture-derived mesenchymal cell (SMCs) suggested that 17-b
estradiol (E2) enhanced both osteogenic and chondrogenic
differentiation within the PF suture. Finally, in vivo blockade of
ER signaling in the developing calvaria via Fulvestrant inhibited
suture fusion and led to severely diminished calvarial osteogenesis.
Discussion
Estrogens have been long considered of importance in bone and
cartilage biology, as well as skeletal development, maturation and
healing [22]. Therefore, natural and synthetic estrogens have been
studied in basic osteochondroblast biology, as well as in clinical
problems as bony non-union, osteoporosis, and osteoarthritis
[33,57,65,66]. In addition, functional estrogen signaling has been
found to be necessary for developmental growth plate fusion [29–
31]. This study addressed a related and straight-forward question:
to what extent does estrogen signaling play a role in the
development and fusion of cranial sutures? To study this, we
chose an animal model of physiologic suture fusion: the mouse
posterofrontal suture.
To date, we are only aware of one other group linking cranial
suture biology with sex hormone signaling [12,13]. Lin et al. in two
publications examined androgen signaling in cranial sutures. They
showed that androgen receptors are strongly expressed in fetal
calvaria and dura mater, that cell culture with the male sex
hormone dihydrotesterone (DHT) increased osteoblastic gene
markers, and sagittal suture organ cultures aberrantly fused with
DHT [12,13]. As in our publication, they found similar patterns of
receptor expression between male and female mice. Other groups
have similarly noted comparable ER expression levels in bony
tissue between the sexes [15,16]. Our findings and others bring to
the fore puzzling questions regarding the specificity of sex
hormones in cranial suture biology. Firstly, despite the clear
effects of hormone signaling on cranial suture fusion, how are
sutures derived from male and female mice morphologically
identical? Next, does genetic deficiency in sex hormone receptors
affect both male and female derived sutures equivalently, or
disparately? Interestingly, the severity of the appendicular skeletal
phenotype of ERKO mice differs by sex [26,27]; it remains
unclear if these differences extend to the craniofacial skeleton. Our
findings by quantitative RT-PCR, immunohistochemistry and cell
culture, however, suggest that estrogens play a relevant role in
suture developmental biology regardless of sex. Analogous findings
are seen clinically as patients with either aromatase deficiency,
ERa deficiency, or androgen insensitivity syndrome, have
osteopenic skeletons, suggesting a need for both androgen and
estrogen receptor signaling for maintenance of bone density. More
detailed study however, particularly in vitro cell culture of male or
female derived cells, is necessary to pursue these conjectures.
Our analysis of ERa and ERb gene expression and ERKO
mice suggest that ER receptors are of unequal importance in
cranial suture biology. Firstly, ERa but not ERb expression
peaked during suture fusion. In fact, ERb expression demonstrat-
ed little change in either fusing (PF) or patent (SAG) sutures
throughout early postnatal development. In addition, the PF
suture of the aERKO mouse exhibited a delayed suture
phenotype. Moreover, thorough analysis of the bERKO mouse
found normal suture morphogenesis, including normal develop-
mental timing of PF suture fusion. Thus, these data suggest that
ERa is of primary, and ERb secondary, importance in cranial
suture biology. Other data support this hypothesis: we noted that
ERa is expressed to a greater degree in the calvaria than ERb.
In our hands, semi-quantitative PCR and Western blot both
showed this to be true: robust bands for ERa expression were seen,
while less intense bands were discernable for ERb expression
(Fig. S3A,B).
Figure 6. Chondrogenic differentiation of PF SMCs with 17-b Estradiol. (A–B) ERa and ERb mRNA expression overtime during in vitro
chondrogenic differentiation. Both transcripts were observed to increased overtime in culture after 6d differentiation. (C) Sox9 expression during
chondrogenic differentiation with or without E2 (10 nM). (D) Col II expression with or without E2 (10 nM). (E) Tgf-b1 expression with or without E2
(10 nm). Values are normalized and significance levels calculated relative to control groups or 0wk expression in grey or blue, N= 3, *P,0.01.
doi:10.1371/journal.pone.0007120.g006
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We observed that application of the pan-ER antagonist Fulvestrant
to the developing mouse calvaria resulted in a substantial decrease in
cranial osteogenesis. While this iatrogenic defect mimicked the
aERKOmouse suture phenotype, it was relatively more severe. How
does one reconcile this difference in severity of phenotype produced
by biochemical blockade versus genetic deficiency? TUNEL staining
excluded cell death among Fulvestrant treated calvaria. One
possibility is that ER genetic deficiency allows time for compensatory
mechanisms to develop, allowing osteoblastic differentiation and
mitigating the aERKO phenotype. In contrast, biochemical ER
blockade via Fulvestrant injection represents a sub-acute insult to the
developing skull, whereby no compensation can ensue. Another
possibility is that intact signaling via ERb may partially mitigate the
aERKO phenotype. Nevertheless, perturbation of ER signaling via
both methods resulted in persistent PF suture patency, and indicated
estrogen/ERa signaling as necessary for normal mouse suture fusion.
In an effort to more fully delineate the importance of ERa vs
ERb signaling, our laboratory has utilized synthetic estrogen
agonists specific for either ERa or ERb in cell culture (propyl
pyrazole triol, PPT, and diarylpropionitrile, DPN, respectively).
Interestingly, our in vitro analysis suggests that both specific
agonists up-regulate osteochondrogenic gene expression in SMCs
(including Runx2 and Sox9, see Fig. S3C,D). How again does this
reconcile with the apparent suture phenotype in the aERKO but
not bERKO mouse? From these data we speculate that estrogen/
ERa signaling may be of principal importance in cranial suture
biology owing to the comparative abundance of receptor
expression in the developing cranial suture complex (Fig.
S3A,B). Conversely, the relatively small expression level of ERb,
as demonstrated on both gene and protein levels, may belie its
importance. Moreover, ERb expression levels were observed to
remain unchanged in the aERKO mouse, which argues against a
Figure 7. Fulvestrant application to mouse calvaria. (A–B) Control treated and Fulvestrant treated calvariae (N = 6, N= 10 respectively) (A)
Dorsal view of p10 bone and cartilage preparation, showing normal calvarial morphogenesis in vehicle treated calvaria. (B) Overhead view of
comparable Fulvestrant treated calvaria. A significant delay in mineralization was observed with widened sutures. (C) Pentachrome staining of p10 PF
suture sectioned in a coronal plane. Normal developmental timing is observed, including progressive fusion and presence of a cartilage intermediate.
(D) Comparable histological section of Fulvestrant treated a p10 PF suture, patency and diminished osteoid is apparent without cartilage. (E–F) Image
of mid-frontal bone in control as compared to Fulvestrant treated calvaria, pentachrome stain. Severely diminished osteoid deposition (appearing
yellow) is apparent among Fulvestrant treated calvaria. (G–H) BrdU incorporation in control in comparison to treated PF sutures. BrdU positive cells
appear brown, while nuclei are counterstained with haemotoxylin. No significant difference was observed between control and Fulvestrant treated
sutures (I–J) TUNEL staining in control and Fulvestrant treated PF sutures. Positive cells appear green. (K–L) TRAP staining in control and Fulvestrant
treated PF sutures. Positively staining cells appear red. (M–N) Runx2 in situ hybridization in control and Fulvestrant treated PF sutures. Positively
staining cells appear purple. (O–P) Shh in situ hybridization in control and Fulvestrant treated PF sutures. Positively staining cells appear purple. (Q)
Quantitative assessments of percentage +BrdU, +TUNEL, or +TRAP stained cells, as calculated using Adobe Photoshop. For quantitative assessments,
values are normalized and significance levels calculated relative to control treated groups shown in grey, *P,0.01.
doi:10.1371/journal.pone.0007120.g007
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functional compensation. More study utilizing specific ER agonists
in vivo may further bring to light the relative importance of ERa
and -b.
Most studies in the field of cranial suture biology have stressed the
relative importance of dura mater in determining fate and timing of
suture development. This includes locoregional production of FGF-2,
TGF-b1, the BMP antagonist Noggin, among others [8,10,67,68].
These paracrine factors are hypothesized to work locally on the
overlying suture mesenchyme, promoting differentiation and ulti-
mately suture fusion [3]. In this conceptual, regulatory framework,
how might an endocrine hormone influence suture fusion? Our study
has identified estrogen responsive cells by localizing ER expression
patterns, but does not indicate a source for estrogen ligands, whether
it be locoregional or distant. Studies in long bones, however, suggest
that production of estrogens by adjacent periosteum affects growth
plate maturation [69,70]. We speculate that dura mater, a known
source of paracrine factors integral to suture fusion, may analogously
be a source of regional estrogen production. More study is needed to
probe this conjecture. Alternatively, those peptide growth factors
known to be localized to PF-associated dura mater (including TGF-b
and IGF-1) have been shown to exert transcriptional effects in an
estrogen receptor-dependent manner [71–73]. Thus, known local
paracrine factors may exert cellular and morphologic effects on the
overlying suture in an ER-dependent manner, either in the absence
or in synergism with E2.
Despite the as yet unclear mechanism whereby E2 may
selectively be involved in PF suture fusion, our in vitro studies in
suture-derived mesenchymal cells (SMCs) suggest a transcriptional
relationship between E2 and other cytokines known to play a role in
suture biology. For example, transcription of a number of pro-
osteogenic BMPs was positively regulated by E2 in PF SMCs in vitro
during osteogenic differentiation (Fig. 4F). Moreover, both Sonic
and Indian Hedgehog, known important players in osteoblast and
chondrocyte differentiation, were up-regulated by E2 as well
(Fig. 4G). In addition, transcription of Tgfb1 was increased with
E2 in PF SMCs (Fig. 6E). Both BMP and TGF-b signaling are
associated with and necessary for physiologic cranial suture fusion
[8,10,11,74], and in our in vitro model system were positively
regulated by E2. Moreover, abundant data in the literature suggest
a positive intersection between estrogen and IGF signaling
[72,73,75,76], another peptide molecule of known importance in
cranial suture fusion [77–79]. We explored this possibility, however
E2 was not observed to significantly effect IGF gene expression in
SMCs in vitro (data not shown). More in vivo correlates must be
sought, but these data potentially implicate estrogen signaling in a
cascade of known molecular mediators in cranial suture fusion.
Especially pertinent to our discussion is the possible relationship
between E2/ERa signaling and Hedgehog (Hh) signaling in
cranial sutures. Interestingly, while the WT posterofrontal cranial
suture shows abundant staining for hedgehog ligands, the aERKO
PF suture did not (Fig. 2G,H). Moreover, Hedgehog signaling was
dynamically regulated by E2 or Fulvestrant in SMCs in vitro
(Fig. 4,5). It is known that mice with genetic deficiency in Ihh have
severe skeletal defects, including severely shortened limbs due to a
defect in endochondral ossification [50]. Moreover, the Ihh null
mouse has a cranial suture phenotype with reduced calvarial bone
size, a phenotype which may have similarities to the aERKO
calvaria, although this has not been well studied [50]. Hedgehog
signaling has been shown to be up-regulated by estrogen signaling
[51,80]. To our knowledge, this is the first publication in which
estrogen signaling has been shown to positively regulate Hedgehog
signaling in bone-forming cells of any type. Moreover, preliminary
data from our laboratory suggests that increased Hedgehog
signaling (via the addition of N-terminal Sonic Hedgehog to
osteogenic medium) significantly enhances the osteogenic differ-
entiation of SMCs in a similar fashion to E2 (data not shown). The
potential cooperative relationship between E2 and Hh signaling
will be the topic of future research.
Important limitations to this study exist toward the extrapola-
tion to the clinical entity of craniosynotosis. The posterofrontal
suture is an example of physiologic suture fusion, and thus has
parallels to the human metopic suture, in both, there exists a
cartilage intermediate preceding closure [4,5]. However, chon-
drogenesis has not been shown to precede clinical craniosynostosis,
whether syndromic or sporadic. Moreover, a cartilaginous
intermediate does not develop in any other sutures of the mouse
skull. Therefore, while this study has immediate applicability to
normal calvarial skeletogenesis and programmed suture fusion, the
relevance of these data to clinical, pathologic suture fusion remains
as yet unclear. ER expression patterns in human synostotic sutures
may yield fruitful insight into the possible connection between
pathologic suture fusion and estrogen signaling.
In conclusion, the role of estrogen signaling is of newly
recognized importance in suture biology. ER gene expression is
associated with physiologic cranial suture fusion. Intact ERa
signaling is necessary for normal mouse cranial suture fusion.
Finally, culture of PF suture-derived cells suggests that estrogen
signaling may positively regulate both osteoblast and chondrocyte
differentiation within the suture complex.
Materials and Methods
Chemicals, supplies and animals
Phenol red-free Dulbecco’s Modified Eagles Medium (DMEM)
and phenol red-free penicillin/streptomycin were purchased
from GIBCO Life Technologies (Carlsbad, CA). Fetal bovine
serum (FBS) was purchased from Omega Scientific (Tarzana,
CA). All cell culture supplies were purchased from Corning Inc.
(San Mateo, CA). RNAeasy kits were purchased from Qiagen
Sciences (Valenica, CA), while other RNA reagents were pur-
chased from Applied Biosystems, (Foster City, CA). Unless
otherwise specified, all other chemicals were purchased from
Sigma-Aldrich (St. Louis, MO).
All experiments followed protocols approved by the Animal
Facilities of Stanford University and the NIEHS/NIH. CD-1 mice
were purchased from Charles Rivers Laboratories (Wilmington,
MA). Male aERKO and bERKO mice on a C57BL/6J
background and wild-type littermates were provided from the
NIEHS, and were genotyped as previously described [81].
Animals were housed in a light and temperature controlled facility
and given food ad libitum. For all experiments, the first day of life
was considered the first day after birth.
Whole mount bone and cartilage preparations
Whole calvariae denuded of skin were fixed overnight in 100%
ethanol (postnatal days 4–19, N= 3–5 per time point from both
male and female mice). Calvariae were then stained with an Alcian
blue solution in 30% acetic acid/70% ethanol to visualize
cartilage. Samples were then washed in 0.5% potassium
hydroxide, stained with an 0.01% Alizarin Red S solution in
0.5% potassium hydroxide to visualize mineralized bone, washed
in PBS, and cleared in a series of graded glycerol. Pictures were
taken at 16–1.66magnification utilizing the Leica digital imaging
system; specimens were stored at room temperature.
Preparation of tissues for histology
Whole calvariae denuded of skin were fixed overnight in 0.4%
paraformaldehyde in PBS at 4uC (postnatal days 4–30, N=2–3
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per time point). Tissue was taken from equal numbers of male and
female mice. PF and SAG sutures with flanking calvarial bones
were dissected, tissue was decalcified in 19% ethylenediaminete-
tracetic acid for 2–14 days at 4uC, dehydrated through graded
ethanol, and paraffin embedded. Coronal sections through PF and
SAG sutures of 5 micron width were mounted on Superfrost plus
slides (Fisher Scientific, Pittsburg, PA), and dried overnight at
37uC. Approximately 200 sections were obtained from each skull;
slides were stored at room temperature.
Histological staining and immunohistochemistry
Every 5th slide of PF and SAG sutures were stained with routine
haematoxylin and eosin. Select slides were stained with penta-
chrome stain to visualize both bone and cartilage, which appear
yellow and blue/green, respectively. Cellular proliferation was
assessed by bromodeoxyuridine (BrdU) and PCNA immunohisto-
chemical staining according to the manufacturer’s instructions
(Zymed, South San Francisco, CA). A haematoxylin counterstain
was employed. BrdU labeling reagent was administered 2 hrs
prior to mouse sacrifice. Cell death was examined by an in situ cell
death detection kit per the manufacturer’s instructions (Roche
Applied Science, Indianapolis, IN). A DAPI counterstain was
employed. Bone turnover was assayed by tartrate resistant acid
phosphatase staining (TRAP staining) according to the manufac-
turer’s recommendations.
Immunohistochemistry was performed on select slides for ERa
and ERb. Slides were deparaffinized and rehydrated. Endogenous
peroxidase activity was quenched with 3% hydrogen peroxide in
methanol; slides were blocked with 10% goat serum in PBS.
Antibodies used included rabbit polyclonal anti-ERa, (1:80 in
dilution, Santa Cruz Laboratories, Santa Cruz, CA), or rabbit
polyclonal anti-ERb (1:2 dilution, BioGenex, San Ramon, CA),
and were suspended in 1% rabbit serum. Appropriate biotinylated
secondary antibodies were used in 1:1000 dilution (Vector
Laboratories, Burlingame, CA). The Vectastain ABC system
(Vector Laboratories, Burlingame, CA) was used according to the
manufacturer’s instructions. Visualization was with diaminobenzi-
dine solution (Zymed Laboratories, South San Francisco, CA).
Slides without primary antibody were used as a negative control.
No less than 5 slides were stained for each antibody, per time
point. To account for possible gender variability, for each time
point immunohistochemistry was performed on equal numbers of
slides taken from both male and female mice. Representative
photographs were taken at 206–406 magnification (Zeiss
Axioplan, Thornwood, NY).
In situ hybridization for Runx2, Ihh and Shh was performed as
previously described [82]. Antisense riboprobe was transcribed in
the presence of Dig-11-UTP (Roche). Sections were incubated for
65uC for 12 hrs in hybridization buffer (Ambion, Austin TX)
containing riboprobe at,1 ug/mL. Slides were blocked with 10%
sheep serum, 2% Boehringer-Mannheim Blocking Reagent
(Roche) and levamisole, and developed using NBT and BCIP
for color.
To assess quantitative differences in staining, Adobe photoshop
was utilized. Pixel number of positively stained cells for BrdU,
TUNEL, TRAP or Shh were quantified from 5 random high-
powered fields using the magic want tool. Values were divided by
the pixel number of DAPI staining in the same images. Means and
standard deviations were calculated.
Quantitative Assesment of Suture Fusion
To assess degree of suture fusion, the entirety of each suture was
sectioned. Every 5th section was stained with H&E (equivalent to
one section per 25 microns), and was evaluated by two independent
observers. Fusion was defined as bony bridging between osteogenic
fronts of the suture, and was considered a binary variable
(1= fusion, 0= patent). In the case of interobserver disagreement,
a third party made the determination. To calculate percentage
fusion, the number of individual slides showing a fused suture was
divided by the total number of stained slides. This method was taken
with adaptation from our previous publication [74].
Quantification of gene expression in cranial sutures in
vivo
Total ribonucleic acid (RNA) was isolated from PF and SAG
suture complexes at stratified postnatal time points (postnatal days
4, 7, 10, 13, 16, 19 - points preceding, during, and after fusion of
the PF suture; N=10 per time point of mixed gender). Calvariae
were dissected in cold, sterile phosphate-buffered saline (PBS).
Pericranium was meticulously removed with fine-tipped forceps
under a dissecting microscope (Dumont #55 Forceps, Fine
Science Tools, Foster City, CA). PF and SAG sutures were then
isolated with 500 micron bony margins on either side as well as
underlying dura mater; dissections were based on previously
established anatomic landmarks [4]. Sutures from each time point
were pooled, snap-frozen in liquid nitrogen, homogenized with a
pestle, and purified using the RNeasy Mini Kit. DNase treatment
was performed with the DNA-free kit according to the manufac-
turer’s instructions (Ambion, Austin, TX). One ug RNA was
reverse transcribed using TaqMANH Reverse Transcription
Reagents. Quantitative real-time polymerase chain reaction
(qRT-PCR) was performed with Power Sybr green detection on a
7900HT Sequence Detection System according to the manufac-
turer’s instructions. Specific primers for the genes examined were
designed based on their PrimerBank sequence (http://pga.mgh.
harvard.edu/primerbank). Primer sequences are shown in
Table 1. PCR products were first run on a 2% agarose gel to
confirm the appropriate size and specificity. Levels of gene
expression were determined by normalizing to their GAPDH
values. All reactions were performed in triplicate.
Protein quantification in whole calvariae in vivo
Protein was isolated from the whole calvaria of p10 mouse skulls
after meticulous dissection of pericranium, dura mater and
ligamentous attachments. 40 ug of total protein extracted with
radioimmunoprecipitation assay (RIPA) buffer (containing 50 mM
Tris-HCl pH 7.5, 150 mM NaCl, 5% Glycerol, 1 mM EDTA,
1% NP-40, 0.1% SDS and 0.25% Na-deoxycholate) was separated
on 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis, transferred to polyvinylidene fluoride membranes, and blocked
with 5% milk/Tris-buffered saline-T for 2 hours. Protein
detection was performed with primary antibodies against ERa
(1:1000 dilution), ERb, and b-actin (1:5000 dilution; Lab Vision,
Fremont, CA) in 5% milk/Tris-buffered saline-T overnight at
4uC. Blots were then incubated with the corresponding horserad-
ish peroxidase-linked secondary antibodies (1:10,000 dilution; BD
Pharmingen, San Jose, CA) for 1 hr at room temperature. Blots
were developed with ECL detection reagent (Amersham, United
Kingdom) and exposed for 1 to 10 minutes using Biomax-MS film
(Eastman Kodak, Rochester, NY).
Tissue harvest and primary cell culture
For all in vitro experiments, PF suture-derived mesenchymal cells
(SMCs) were harvested from 200 four-day-old CD1 mice via non-
enzymatic primary cell harvest as previously described [7,8,32,83].
PF sutures were dissected with 500 um bony margins, meticulously
stripped of all pericranial and dural tissues, and plated in 100-mm
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tissue culture dishes (endocranial surface was placed flush to the
culture dish, approximately 10 sutures per plate). Explants were
cultured in growth medium containing DMEM, 10% FBS, 100
IU/ml of penicillin/streptomycin, and maintained at 37uC in an
atmosphere of 5% CO2. Phenol red-free culture medium was used
in all assays to avoid its estrogenic effects. Over seven days in
culture, SMCs were allowed to migrate from suture explants;
cellular yield was approximately 100,000 cells per suture explant.
SMCs were passaged by trypsinization; passage one SMCs only
were used for all experiments.
Cellular proliferation assays
The growth of SMCs in response to 17-b estradiol (E2) or
Fulvestrant was compared by BrdU incorporation assays as
previously described (N= 6) [32]. Cells were seeded in 96-well
plates at a density of 1,000 cells/well and were treated with growth
medium supplemented with E2 (0.1–100 nM), Fulvestrant (0.1–
10 uM), or vehicle as a control (10 ug/ml bovine serum albumin
or 0.1% dimethyl sulfoxide, respectively). At 3d and 6d growth,
BrdU incorporation assays were performed according to the
manufacturer’s instruction (Roche Applied Science, Indianapolis,
IN). Labeling with BrdU was performed for a period of 8 hrs.
Means and standard deviations were calculated.
Osteogenic differentiation and assessments
Cells were plated in 24-well plates at a density of 10,000 cells/well,
and were treated with osteogenic differentiation medium (ODM)
containing DMEM, 10% FBS, 100 mg/ml ascorbic acid, 10 mM b-
glycerophosphate, 100 IU/ml penicillin/streptomycin as previously
described [32]. ODM was supplemented with E2 (1–100 nM),
Fulvestrant (0.1–10 uM), the ERa specific agonist propyl pyrazole
triol (PPT, 1–100 nM), ERb specific agonist diarylpropionitrile
(DPN, 1–100 nM), or with vehicle as a control (Sigma-Aldrich, St.
Louis, MO).
To assess early osteogenic differentiation, alkaline phospha-
tase (ALP) staining and quantification was performed after 7d
differentiation as previously described [32]. For staining, cells
were fixed with a 60% acetone, 40% citrate solution, and stained
with a diazonium salt with 4% napthol AS-MX phosphate
alkaline solution. Alkaline phosphatase positive cells were
stained purple. For ALP quantification, protein was isolated in
RIPA buffer. The alkaline phosphate activity was assayed by
measuring the p-nitrophenol formed from the enzymatic
hydrolysis of p-nitrophenylphosphate. Experiments were per-
formed in triplicate wells; means and standard deviations were
calculated.
After 14d osteogenic differentiation, Alizarin red S staining was
performed to detect extracellular mineralization as previously
described [32]. Briefly, cells were fixed in 100% ethanol and
stained with a 0.2% Alizarin red S solution. The red staining
represents calcium deposits on differentiated cells.
Finally, total RNA was isolated from SMCs at 2, 4, 7, and 14d
of osteogenic differentiation. Gene expression of the transcription
factor Runx2, as well as other markers of osteogenesis (Alkaline
phosphatase, Collagen Type 1a, Osteopontin, Osteocalcin, Bone morphogenetic
protein-2, -4, -7, Sonic Hedgehog, Indian Hedgehog, Gli1, Ptc1, Sex
determining region Y-box 9 (Sox9), ERa, ERb) was evaluated by
quantitative RT-PCR.
Chondrogenic differentiation and assessments
Cells were plated in 12-well plates at a high density of 70,000
cells/well; SMCs were treated with chondrogenic differentiation
medium containing DMEM, 1% FBS, 37.5 ug/ml ascorbate-2-
phophate, ITS premix (BD Biosciences, Franklin Lakes, NJ), and
100 IU/ml penicillin and streptomycin as previously described
[7,8]. E2 (10 nM) or vehicle as a control was supplemented to
chondrogenic medium. Medium was supplemented every three
days. At 3, 6, and 9d of differentiation, RNA was isolated and gene
Table 1. Quantitative PCR Genes and Primer Sequences.
Gene Name NCBI GeneID Forward primer sequence (59 to 39) Reverse primer sequence (59 to 39)
Alkaline phosphatase 11647 GTTGCCAAGCTGGGAAGAACAC CCCACCCCGCTATTCCAAAC
Bmp2 12156 GGGACCCGCTGTCTTCTAGT TCAACTCAAATTCGCTGAGGAC
Bmp4 12159 TTCCTGGTAACCGAATGCTGA CCTGAATCTCGGCGACTTTTT
Bmp7 12162 CGATACCACCATCGGGAGTTC AAGGTCTCGTTGTCAAATCGC
Collagen Type IaI (ColIaI) 12814 AACCCGAGGTATGCTTGATCT CCAGTTCTTCATTGCATTGC
Collagen Type II (Col II) 12824 TCCAGATGACTTTCCTCCGTCTA CAGGTAGGCGATGCTGTTCTTAC
Estrogen Receptor a (ERa) 13982 CCTCCCGCCTTCTACAGGT CACACGGCACAGTAGCGAG
Estrogen Receptor b (ERb) 13983 CTGTGATGAACTACAGTGTTCCC CACATTTGGGCTTGCAGTCTG
GAPDH 14433 AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA
Gli1 14632 TCGACCTGCAAACCGTAATCC TCCTAAAGAAGGGCTCATGGTA
Indian hedgehog (Ihh) 16147 GCTTCGACTGGGTGTATTACG GCTCGCGGTCCAGGAAAAT
Osteocalcin (Oc) 12096 GGGAGACAACAGGGAGGAAAC CAGGCTTCCTGCCAGTACCT
Osteopontin (Opn) 20750 TAGCTTGGCTTATGGACTGAGG AGACTCACCGCTCTTCATGTG
Patched (Ptc1) 19206 GCCAAGCCCTAAAAAAAT ACCACAATCAATCTCCTG
Runx2 12393 CGGTCTCCTTCCAGGATGGT GCTTCCGTCAGCGTCAACA
Sonic hedgehog (Shh) 20423 AAAGCTGACCCTTTAGCCTA TTCGGAGTTTCTTGTGATCTTCC
Sox9 20682 TACGACTGGACGCTGGTGC TTCATGGGTCGCTTGACGT
Tgfb1 21803 AACAATTCCTGGCGTTACCTT TCCTTCCACAGTATGCTCGTA
doi:10.1371/journal.pone.0007120.t001
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markers of chondrogenesis were examined by real-time PCR
(Sox9, Collagen Type II, TGF-b1, ERa, ERb). Primer sequences are
listed in Table 1.
In vivo Fulvestrant application and assessments
To test the necessity of estrogen signaling in the suture fusion,
the synthetic pan-ER antagonist Fulvestrant was applied in vivo.
Starting at birth, 10 ul of a 100 uM solution Fulvestrant (in a
suspension containing 0.9% normal saline, 0.01% DMSO) was
injected subcutaneously, daily, directly overlying the midline
sutures. Vehicle (0.9% normal saline, 0.01% DMSO) was injected
in littermates as a control. Skulls were harvested at p10 for analysis
by whole mount bone and cartilage preparations, as well as serial
coronal sections for histology.
Statistical analysis
Means and standard deviations were calculated from numerical
data, as presented in the text, figures, and figure legends. In
graphs, columns represent means whereas error bars represent one
standard deviation. Statistical analysis was performed using the
ANOVA two-factor with replication when more than two factors
were compared. In supplement, the Welch’s two-tailed t-test was
used when standard deviations between groups were unequal.
*P#0.01 was considered to be significant.
Supporting Information
Figure S1 Gross morphology of PF and SAG sutures. Whole
mount bone (red) and cartilage (blue) preparations of mouse
calvaraie, ages postnatal day (p)4 through 19. The posterofrontal
(PF) suture lies anterior (above in this orientation), while the
sagittal (SAG) suture lies posterior (below). (A) At p4, both PF and
SAG sutures are widely separated. (B–E) Islands of bony bridging
are observed within the PF suture (p7–16). (F) By p19 (bottom
right), the PF suture is largely fused. Note that tongues of cartilage
(stained blue) are observed in the early postnatal skull base (p4, p7).
Degree of red hue generally represents thickness of mineralized
bone, with the exception of the area of the coronal (COR) suture,
where this represents overlap of one calvarial bone on another;
photographs are taken at 1.66magnification.
Found at: doi:10.1371/journal.pone.0007120.s001 (3.44 MB TIF)
Figure S2 Histological morphology of PF and SAG sutures.
Pentachrome staining of coronal sections through PF and SAG
sutures, p4–p19. Osteoid appears yellow, while glycosaminoglycan
in cartilage appear blue/green. In the PF suture (first and third
columns), a cartilaginous intermediate is apparent from p7 to p13
located on the endocranial aspect of the suture (C–F,M,N). From
p16 onwards, osseous fusion of the PF suture can be observed (O–
R). In contrast, an undifferentiated cellular mesenchyme is
observed at all time points in the SAG suture with maintenance
of suture patency, (second and fourth columns). Photographs are
taken from the anterior aspect of PF and SAG sutures, and are at
206 and 406magnification.
Found at: doi:10.1371/journal.pone.0007120.s002 (7.50 MB TIF)
Figure S3 Comparison of Estrogen Receptor Expression and
Stimulation (A) Expression of ERa and ERb within the p10 mouse
skull by semi-quantitative PCR at 30 cycles. ERa is expressed to a
greater degree than is ERb. (B) Expression of ERa and ERb
within the p10 mouse skull by western blot. Experiments were
performed in triplicate; mouse uterine tissue was used as a positive
control. (B–C) PF SMCs were cultured with or without the ER
specific agonists PPT or DPN (ERa and ERb specific agonists,
respectively). Runx2 and Sox9 expression was evaluated after
48 hrs. Results showed that both PPT and DPN significantly and
dose-dependently increased Runx2 and Sox9 expression in PF
SMCs. No difference was observed between ERa and ERb
specific agonists. Values are normalized and significance levels
calculated relative to control groups, N= 3, *P,0.01.
Found at: doi:10.1371/journal.pone.0007120.s003 (5.17 MB TIF)
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